Pharmaceutical company Brill Pharma moves to Barcelona creating 75 new jobs
The new subsidiary of British Bristol Laboratories group will open up markets in Spain, Portugal and Latin America.
By Biocat
Brill Pharma, which belongs to one of the main pharmaceutical groups in the United Kingdom, Bristol Laboratories, has chosen Barcelona as the location of their headquarters for the Spanish, Portuguese and Latin American markets. The CEO of the pharmaceutical company’s new subsidiary is Jordi Martínez (Manresa, 1969) who currently also presides over Plasmia Biotech (with equity holder InKemia IUCT Group).
The new headquarters on Carrer Mandri will be home to a 75-person team but, as Jordi Martínez explained in an interview with Spanish economic newspaper Expansión, the Spanish subsidiary of Brill Pharma “aims to increase personnel as more products are launched to market”. The pharmaceutical company currently markets nine products in the fields of dermatology, ophthalmology and gynecology, under four lines Mask, Hylo, Elynor and Ciruplas. Jordi Martínez has announced that the company is trying to establish an alliance with Galicia-based Biofabri to begin work at their production plant in Porriño, previously held by British AstraZeneca.
Bristol Laboratories has a yearly turnover of nearly €120 millions and staff of more than 500 workers in production plants in Germany, the United Kingdom and India. They are currently the main producer, distributor and marketer of generics in the United Kingdom. In the coming two years, according to Martínez, they expect to launch a line of generics on the Spanish market, after they have consolidated their presence with brand-name drugs.
Large pharma companies have subsidiaries in Catalonia
Brill Pharma’s decision to establish this subsidiary in Barcelona further reinforces international presence in the BioRegion of Catalonia, where eight of the ten large pharmaceutical groups have branches: Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Grupo Roche, Novartis, Pfizer, Sanofi-Aventis and Takeda.
The Spanish pharmaceutical sector is concentrated mainly in Catalonia (46%), which is home to the headquarters of top industry players like Almirall, Esteve, Ferrer Grupo and Grupo Uriach and where 60% of all Spanish pharmaceutical production takes place and where 50% of all chemical products are exported from.